Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Transfusion. 2013 Apr 29;54(1):179–189. doi: 10.1111/trf.12217

Figure 2. C57BL/6 recipients lacking human KEL have a dose dependent anti-KEL glycoprotein antibody response.

Figure 2

(A) Control (KEL2) or wild type C57BL/6 recipients were transfused with 0.5, 5, or 50 μL of KEL2 RBCs, with serum anti-KEL glycoprotein IgG evaluated 2 weeks post-transfusion. Serial evaluations of serum anti-KEL glycoprotein IgM (B) or IgG (C) were completed in KEL2 or wild type C57BL/6 recipients after a single transfusion of 50 μL of KEL2 RBCs. Results are representative of 2–3 independent experiments with at least 3–5 mice/group; *p<0.05.